News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
804,407 Results
Type
Article (60031)
Company Profile (484)
Press Release (743873)
Multimedia
Podcasts (179)
Webinars (27)
Section
Business (224952)
Career Advice (2732)
Deals (38308)
Drug Delivery (144)
Drug Development (88117)
Employer Resources (182)
FDA (17779)
Job Trends (16525)
News (379988)
Policy (36492)
Tag
2027 Biotech Bay Standard (2)
2027 Genetown Elite (2)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2922)
Academic (2)
Accelerated approval (35)
Adcomms (30)
Allergies (151)
Alliances (55603)
ALS (183)
Alzheimer's disease (1784)
Antibody-drug conjugate (ADC) (352)
Approvals (18002)
Artificial intelligence (606)
Autoimmune disease (176)
Automation (40)
Bankruptcy (389)
Best Places to Work (12378)
BIOSECURE Act (22)
Biosimilars (207)
Biotechnology (311)
Bladder cancer (159)
Brain cancer (64)
Breast cancer (671)
Cancer (5091)
Cardiovascular disease (450)
Career advice (2317)
Career pathing (42)
CAR-T (308)
CDC (54)
Celiac Disease (2)
Cell therapy (826)
Cervical cancer (38)
Clinical research (74655)
Collaboration (1876)
Company closure (5)
Compensation (1201)
Complete response letters (70)
COVID-19 (2956)
CRISPR (103)
C-suite (918)
Cystic fibrosis (154)
Data (6430)
Decentralized trials (2)
Denatured (64)
Depression (154)
Diabetes (535)
Diagnostics (7125)
Digital health (53)
Diversity (13)
Diversity, equity & inclusion (46)
Drug discovery (294)
Drug pricing (222)
Drug shortages (32)
Duchenne muscular dystrophy (243)
Earnings (96738)
Editorial (67)
Employer branding (22)
Employer resources (162)
Events (130078)
Executive appointments (1051)
FDA (21034)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (11)
Frontotemporal dementia (24)
Funding (1581)
Gene editing (221)
Generative AI (61)
Gene therapy (674)
GLP-1 (1111)
Government (5190)
Grass and pollen (8)
Guidances (386)
Healthcare (20311)
HIV (65)
Huntington's disease (50)
IgA nephropathy (88)
Immunology and inflammation (296)
Immuno-oncology (64)
Indications (113)
Infectious disease (3248)
Inflammatory bowel disease (209)
Inflation Reduction Act (17)
Influenza (124)
Intellectual property (261)
Interviews (472)
IPO (17530)
IRA (61)
Job creations (4523)
Job search strategy (1928)
JPM (71)
Kidney cancer (16)
Labor market (88)
Layoffs (632)
Leadership (38)
Legal (9076)
Liver cancer (98)
Longevity (15)
Lung cancer (680)
Lymphoma (388)
Machine learning (44)
Management (63)
Manufacturing (870)
MASH (177)
Medical device (14754)
Medtech (14812)
Mergers & acquisitions (21866)
Metabolic disorders (1399)
Multiple sclerosis (171)
NASH (21)
Neurodegenerative disease (362)
Neuropsychiatric disorders (102)
Neuroscience (3134)
Neurotech (1)
NextGen: Class of 2026 (7270)
Non-profit (4945)
Now hiring (67)
Obesity (673)
Opinion (326)
Ovarian cancer (171)
Pain (219)
Pancreatic cancer (240)
Parkinson's disease (302)
Partnered (37)
Patents (523)
Patient recruitment (516)
Peanut (60)
People (64780)
Pharmaceutical (111)
Pharmacy benefit managers (33)
Phase 1 (23265)
Phase 2 (32687)
Phase 3 (24483)
Pipeline (5503)
Policy (325)
Postmarket research (2946)
Preclinical (10128)
Press Release (72)
Prostate cancer (253)
Psychedelics (57)
Radiopharmaceuticals (305)
Rare diseases (936)
Real estate (6885)
Recruiting (74)
Regulatory (26971)
Reports (54)
Research institute (2675)
Resumes & cover letters (438)
Rett syndrome (28)
RNA editing (20)
RSV (86)
Schizophrenia (162)
Series A (261)
Series B (204)
Service/supplier (14)
Sickle cell disease (106)
Special edition (27)
Spinal muscular atrophy (169)
Sponsored (49)
Startups (4134)
State (2)
Stomach cancer (20)
Supply chain (114)
Tariffs (98)
The Weekly (113)
Vaccines (1137)
Venture capital (100)
Weight loss (459)
Women's health (96)
Worklife (21)
Date
Today (138)
Last 7 days (595)
Last 30 days (2329)
Last 365 days (31919)
2026 (3867)
2025 (32254)
2024 (37372)
2023 (42218)
2022 (53610)
2021 (58335)
2020 (57075)
2019 (50281)
2018 (38159)
2017 (35557)
2016 (35785)
2015 (41863)
2014 (36218)
2013 (31922)
2012 (33683)
2011 (33991)
2010 (32430)
Location
Africa (1010)
Alabama (92)
Alaska (7)
Arizona (331)
Arkansas (14)
Asia (47297)
Australia (7838)
California (11709)
Canada (3371)
China (1194)
Colorado (501)
Connecticut (512)
Delaware (353)
Europe (105111)
Florida (1742)
Georgia (370)
Hawaii (3)
Idaho (64)
Illinois (934)
India (71)
Indiana (552)
Iowa (23)
Japan (450)
Kansas (133)
Kentucky (42)
Louisiana (28)
Maine (83)
Maryland (1458)
Massachusetts (8559)
Michigan (358)
Minnesota (663)
Mississippi (5)
Missouri (141)
Montana (35)
Nebraska (29)
Nevada (126)
New Hampshire (85)
New Jersey (3133)
New Mexico (33)
New York (3095)
North Carolina (1592)
North Dakota (10)
Northern California (5675)
Ohio (357)
Oklahoma (23)
Oregon (47)
Pennsylvania (2345)
Puerto Rico (25)
Rhode Island (49)
South America (1379)
South Carolina (68)
South Dakota (1)
Southern California (4541)
Tennessee (178)
Texas (1824)
United States (42037)
Utah (353)
Vermont (1)
Virginia (291)
Washington D.C. (86)
Washington State (975)
West Virginia (4)
Wisconsin (132)
Wyoming (2)
804,407 Results for "otsuka pharmaceutical development and commercialization inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
4DMT Announces Exclusive License Agreement with Otsuka Pharmaceutical Co., Ltd. for Development and Commercialization of 4D-150 in Asia-Pacific
October 31, 2025
·
8 min read
Press Releases
Sky Labs Signs Exclusive Distribution Agreement with Otsuka Pharmaceutical for ‘CART BP pro’ in Japan
February 6, 2026
·
4 min read
Press Releases
Biodexa Announces Exclusive License of Otsuka’s OPB-171775, a potent Phase 1 ready Molecular Glue for GIST
February 5, 2026
·
7 min read
Deals
4DMT Sends Eye Disease Asset’s Asia Rights to Otsuka for $85M Upfront
Otsuka Pharmaceuticals could shell out over $400 million in total for the Asia-Pacific rights to 4D-150, which combines a VEGF-C inhibitory RNAi with Regeneron’s Eylea into a single ocular injection.
October 31, 2025
·
1 min read
·
Annalee Armstrong
Press Releases
Otsuka Announces FDA Acceptance and Priority Review of New Drug Application for Centanafadine for the Treatment of ADHD in Children, Adolescents, and Adults
January 28, 2026
·
5 min read
Approvals
Otsuka Secures IgAN Win as FDA Approves First Anti-APRIL Antibody
Analysts at Guggenheim Partners expect Voyxact to see “broad commercial uptake” given its relatively broad label compared with previous accelerated approvals for IgA nephropathy.
November 26, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Otsuka Pharmaceutical Submits New Drug Application to U.S. FDA for Centanafadine for the Treatment of ADHD in Children, Adolescents, and Adults
November 25, 2025
·
8 min read
Adcomms
Otsuka, Lundbeck Fail To Sway Adcomm on Rexulti Combo for PTSD
Otsuka and Lundbeck’s data are insufficient to establish significant efficacy of Rexulti plus sertraline in PTSD, according to the FDA’s outside experts.
July 21, 2025
·
2 min read
·
Tristan Manalac
IgA nephropathy
Otsuka Sees ‘Impressive’ Proteinuria Reduction in Phase III IgAN Trial
Otsuka’s investigational antibody sibeprenlimab approximately halved levels of this key biomarker in patients with immunoglobulin A nephropathy.
June 6, 2025
·
2 min read
·
Tristan Manalac
Pharm Country
Otsuka to Terminate Development of AVP-786
Otsuka Pharmaceutical Co., Ltd. and its U.S. subsidiary, Otsuka Pharmaceutical Development & Commercialization, Inc. announce termination of development of the novel compound AVP-786, which was in development as a potential treatment for patients with agitation associated with dementia due to Alzheimer’s disease.
May 22, 2024
·
2 min read
1 of 80,441
Next
